Differences in Allelic Frequency and CDRH3 Region Limit the Engagement of HIV Env Immunogens by Putative VRC01 Neutralizing Antibody Precursors

Cell Reports

Volumn 17, Issue 6, 2016, Pages 1560-1570

  Yacoob, Christina ^a   Pancera, Marie ^a,b   Vigdorovich, Vladimir ^c   Oliver, Brian G ^c   Glenn, Jolene A ^a   Feng, Junli ^a   Sather, D Noah ^c   McGuire, Andrew T ^a   Stamatatos, Leonidas ^a,d  

^a Fred Hutchinson Cancer Research Center   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

broadly neutralizing antibodies; CDRH3; germline; HIV; human alleles; human antibodies; VRC01

Indexed keywords

B LYMPHOCYTE RECEPTOR; CDRH3 PROTEIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VRC01 NEUTRALIZING ANTIBODY; IMMUNOGLOBULIN M; PROTEIN BINDING;

ANTIBODY PRODUCTION; ANTIBODY STRUCTURE; ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; GENE FREQUENCY; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MODEL; NONHUMAN; PRIORITY JOURNAL; ALLELE; AMINO ACID SEQUENCE; B LYMPHOCYTE; CHEMISTRY; COMPLEMENTARITY DETERMINING REGION; GENETICS; GERM CELL; IMMUNOLOGY; METABOLISM; PROTEIN DOMAIN;

ALLELES; AMINO ACID SEQUENCE; ANTIBODIES, NEUTRALIZING; B-LYMPHOCYTES; COMPLEMENTARITY DETERMINING REGIONS; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENE FREQUENCY; GERM CELLS; HIV-1; HUMANS; IMMUNOGLOBULIN M; PROTEIN BINDING; PROTEIN DOMAINS;

EID: 84995572399     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.10.017     Document Type: Article

References (48)

1. Balazs, A.B., Ouyang, Y., Hong, C.M., Chen, J., Nguyen, S.M., Rao, D.S., An, D.S., Baltimore, D., Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission. Nat. Med. 20 (2014), 296–300.
2. Bonsignori, M., Zhou, T., Sheng, Z., Chen, L., Gao, F., Joyce, M.G., Ozorowski, G., Chuang, G.Y., Schramm, C.A., Wiehe, K., et al., NISC Comparative Sequencing Program. Maturation pathway from germline to broad HIV-1 neutralizer of a CD4-mimic antibody. Cell 165 (2016), 449–463.
3. Caskey, M., Klein, F., Lorenzi, J.C., Seaman, M.S., West, A.P. Jr., Buckley, N., Kremer, G., Nogueira, L., Braunschweig, M., Scheid, J.F., et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522 (2015), 487–491.
4. Chen, L., Kwon, Y.D., Zhou, T., Wu, X., O'Dell, S., Cavacini, L., Hessell, A.J., Pancera, M., Tang, M., Xu, L., et al. Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 326 (2009), 1123–1127.
5. DeKosky, B.J., Kojima, T., Rodin, A., Charab, W., Ippolito, G.C., Ellington, A.D., Georgiou, G., In-depth determination and analysis of the human paired heavy- and light-chain antibody repertoire. Nat. Med. 21 (2015), 86–91.
6. Diskin, R., Scheid, J.F., Marcovecchio, P.M., West, A.P. Jr., Klein, F., Gao, H., Gnanapragasam, P.N., Abadir, A., Seaman, M.S., Nussenzweig, M.C., Bjorkman, P.J., Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science 334 (2011), 1289–1293.
7. Doria-Rose, N.A., Klein, R.M., Daniels, M.G., O'Dell, S., Nason, M., Lapedes, A., Bhattacharya, T., Migueles, S.A., Wyatt, R.T., Korber, B.T., et al. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J. Virol. 84 (2010), 1631–1636.
8. Doria-Rose, N.A., Schramm, C.A., Gorman, J., Moore, P.L., Bhiman, J.N., DeKosky, B.J., Ernandes, M.J., Georgiev, I.S., Kim, H.J., Pancera, M., et al., NISC Comparative Sequencing Program. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 509 (2014), 55–62.
9. Dosenovic, P., von Boehmer, L., Escolano, A., Jardine, J., Freund, N.T., Gitlin, A.D., McGuire, A.T., Kulp, D.W., Oliveira, T., Scharf, L., et al. Immunization for HIV-1 broadly neutralizing antibodies in human Ig knockin mice. Cell 161 (2015), 1505–1515.
10. Gao, F., Bonsignori, M., Liao, H.X., Kumar, A., Xia, S.M., Lu, X., Cai, F., Hwang, K.K., Song, H., Zhou, T., et al. Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies. Cell 158 (2014), 481–491.
11. Goo, L., Chohan, V., Nduati, R., Overbaugh, J., Early development of broadly neutralizing antibodies in HIV-1-infected infants. Nat. Med. 20 (2014), 655–658.
12. Gray, E.S., Madiga, M.C., Hermanus, T., Moore, P.L., Wibmer, C.K., Tumba, N.L., Werner, L., Mlisana, K., Sibeko, S., Williamson, C., et al., CAPRISA002 Study Team. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J. Virol. 85 (2011), 4828–4840.
13. He, L., Sok, D., Azadnia, P., Hsueh, J., Landais, E., Simek, M., Koff, W.C., Poignard, P., Burton, D.R., Zhu, J., Toward a more accurate view of human B-cell repertoire by next-generation sequencing, unbiased repertoire capture and single-molecule barcoding. Sci. Rep., 4, 2014, 6778.
14. Hoot, S., McGuire, A.T., Cohen, K.W., Strong, R.K., Hangartner, L., Klein, F., Diskin, R., Scheid, J.F., Sather, D.N., Burton, D.R., Stamatatos, L., Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. PLoS Pathog., 9, 2013, e1003106.
15. Hraber, P., Seaman, M.S., Bailer, R.T., Mascola, J.R., Montefiori, D.C., Korber, B.T., Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS 28 (2014), 163–169.
16. Jardine, J., Julien, J.P., Menis, S., Ota, T., Kalyuzhniy, O., McGuire, A., Sok, D., Huang, P.S., MacPherson, S., Jones, M., et al. Rational HIV immunogen design to target specific germline B cell receptors. Science 340 (2013), 711–716.
17. Jardine, J.G., Kulp, D.W., Havenar-Daughton, C., Sarkar, A., Briney, B., Sok, D., Sesterhenn, F., Ereño-Orbea, J., Kalyuzhniy, O., Deresa, I., et al. HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen. Science 351 (2016), 1458–1463.
18. Klein, F., Diskin, R., Scheid, J.F., Gaebler, C., Mouquet, H., Georgiev, I.S., Pancera, M., Zhou, T., Incesu, R.B., Fu, B.Z., et al. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell 153 (2013), 126–138.
19. Kwong, P.D., Mascola, J.R., Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 37 (2012), 412–425.
20. Liao, H.X., Lynch, R., Zhou, T., Gao, F., Alam, S.M., Boyd, S.D., Fire, A.Z., Roskin, K.M., Schramm, C.A., Zhang, Z., et al., NISC Comparative Sequencing Program. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496 (2013), 469–476.
21. Lin, S.G., Ba, Z., Du, Z., Zhang, Y., Hu, J., Alt, F.W., Highly sensitive and unbiased approach for elucidating antibody repertoires. Proc. Natl. Acad. Sci. USA 113 (2016), 7846–7851.
22. Lynch, R.M., Boritz, E., Coates, E.E., DeZure, A., Madden, P., Costner, P., Enama, M.E., Plummer, S., Holman, L., Hendel, C.S., et al., VRC 601 Study Team. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci. Transl. Med., 7, 2015, 319ra206.
23. Lynch, R.M., Wong, P., Tran, L., O'Dell, S., Nason, M.C., Li, Y., Wu, X., Mascola, J.R., HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies. J. Virol. 89 (2015), 4201–4213.
24. Lyumkis, D., Julien, J.P., de Val, N., Cupo, A., Potter, C.S., Klasse, P.J., Burton, D.R., Sanders, R.W., Moore, J.P., Carragher, B., et al. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 342 (2013), 1484–1490.
25. McGuire, A.T., Hoot, S., Dreyer, A.M., Lippy, A., Stuart, A., Cohen, K.W., Jardine, J., Menis, S., Scheid, J.F., West, A.P., et al. Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. J. Exp. Med. 210 (2013), 655–663.
26. McGuire, A.T., Gray, M.D., Dosenovic, P., Gitlin, A.D., Freund, N.T., Petersen, J., Correnti, C., Johnsen, W., Kegel, R., Stuart, A.B., et al. Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice. Nat. Commun., 7, 2016, 10618.
27. Mikell, I., Sather, D.N., Kalams, S.A., Altfeld, M., Alter, G., Stamatatos, L., Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog., 7, 2011, e1001251.
28. Piantadosi, A., Panteleeff, D., Blish, C.A., Baeten, J.M., Jaoko, W., McClelland, R.S., Overbaugh, J., Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J. Virol. 83 (2009), 10269–10274.
29. Pietzsch, J., Gruell, H., Bournazos, S., Donovan, B.M., Klein, F., Diskin, R., Seaman, M.S., Bjorkman, P.J., Ravetch, J.V., Ploss, A., Nussenzweig, M.C., A mouse model for HIV-1 entry. Proc. Natl. Acad. Sci. USA 109 (2012), 15859–15864.
30. Sanders, R.W., van Gils, M.J., Derking, R., Sok, D., Ketas, T.J., Burger, J.A., Ozorowski, G., Cupo, A., Simonich, C., Goo, L., et al. HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science, 349, 2015, aac4223.
31. Sather, D.N., Armann, J., Ching, L.K., Mavrantoni, A., Sellhorn, G., Caldwell, Z., Yu, X., Wood, B., Self, S., Kalams, S., Stamatatos, L., Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83 (2009), 757–769.
32. Scharf, L., West, A.P. Jr., Gao, H., Lee, T., Scheid, J.F., Nussenzweig, M.C., Bjorkman, P.J., Diskin, R., Structural basis for HIV-1 gp120 recognition by a germ-line version of a broadly neutralizing antibody. Proc. Natl. Acad. Sci. USA 110 (2013), 6049–6054.
33. Scharf, L., West, A.P., Sievers, S.A., Chen, C., Jiang, S., Gao, H., Gray, M.D., McGuire, A.T., Scheid, J.F., Nussenzweig, M.C., et al. Structural basis for germline antibody recognition of HIV-1 immunogens. eLife, 5, 2016, e13783.
34. Scheid, J.F., Mouquet, H., Ueberheide, B., Diskin, R., Klein, F., Oliveira, T.Y., Pietzsch, J., Fenyo, D., Abadir, A., Velinzon, K., et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333 (2011), 1633–1637.
35. Shingai, M., Donau, O.K., Plishka, R.J., Buckler-White, A., Mascola, J.R., Nabel, G.J., Nason, M.C., Montefiori, D., Moldt, B., Poignard, P., et al. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J. Exp. Med. 211 (2014), 2061–2074.
36. Simek, M.D., Rida, W., Priddy, F.H., Pung, P., Carrow, E., Laufer, D.S., Lehrman, J.K., Boaz, M., Tarragona-Fiol, T., Miiro, G., et al. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J. Virol. 83 (2009), 7337–7348.
37. Stewart-Jones, G.B., Soto, C., Lemmin, T., Chuang, G.Y., Druz, A., Kong, R., Thomas, P.V., Wagh, K., Zhou, T., Behrens, A.J., et al. Trimeric HIV-1-Env structures define glycan shields from clades A, B, and G. Cell 165 (2016), 813–826.
38. van Gils, M.J., Euler, Z., Schweighardt, B., Wrin, T., Schuitemaker, H., Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression. AIDS 23 (2009), 2405–2414.
39. Wardemann, H., Yurasov, S., Schaefer, A., Young, J.W., Meffre, E., Nussenzweig, M.C., Predominant autoantibody production by early human B cell precursors. Science 301 (2003), 1374–1377.
40. West, A.P. Jr., Diskin, R., Nussenzweig, M.C., Bjorkman, P.J., Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. Proc. Natl. Acad. Sci. USA 109 (2012), E2083–E2090.
41. Wu, X., Yang, Z.Y., Li, Y., Hogerkorp, C.M., Schief, W.R., Seaman, M.S., Zhou, T., Schmidt, S.D., Wu, L., Xu, L., et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329 (2010), 856–861.
42. Wu, X., Zhou, T., Zhu, J., Zhang, B., Georgiev, I., Wang, C., Chen, X., Longo, N.S., Louder, M., McKee, K., et al., NISC Comparative Sequencing Program. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333 (2011), 1593–1602.
43. Wu, X., Wang, C., O'Dell, S., Li, Y., Keele, B.F., Yang, Z., Imamichi, H., Doria-Rose, N., Hoxie, J.A., Connors, M., et al. Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site. J. Virol. 86 (2012), 5844–5856.
44. Wu, X., Zhang, Z., Schramm, C.A., Joyce, M.G., Kwon, Y.D., Zhou, T., Sheng, Z., Zhang, B., O'Dell, S., McKee, K., et al., NISC Comparative Sequencing Program. Maturation and diversity of the VRC01-antibody lineage over 15 years of chronic HIV-1 infection. Cell 161 (2015), 470–485.
45. Zhou, T., Georgiev, I., Wu, X., Yang, Z.Y., Dai, K., Finzi, A., Kwon, Y.D., Scheid, J.F., Shi, W., Xu, L., et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329 (2010), 811–817.
46. Zhou, T., Zhu, J., Wu, X., Moquin, S., Zhang, B., Acharya, P., Georgiev, I.S., Altae-Tran, H.R., Chuang, G.Y., Joyce, M.G., et al., NISC Comparative Sequencing Program. Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. Immunity 39 (2013), 245–258.
47. Zhou, T., Lynch, R.M., Chen, L., Acharya, P., Wu, X., Doria-Rose, N.A., Joyce, M.G., Lingwood, D., Soto, C., Bailer, R.T., et al., NISC Comparative Sequencing Program. Structural repertoire of HIV-1-neutralizing antibodies targeting the CD4 supersite in 14 donors. Cell 161 (2015), 1280–1292.
48. Zhu, J., Wu, X., Zhang, B., McKee, K., O'Dell, S., Soto, C., Zhou, T., Casazza, J.P., Mullikin, J.C., Kwong, P.D., et al., NISC Comparative Sequencing Program. De novo identification of VRC01 class HIV-1-neutralizing antibodies by next-generation sequencing of B-cell transcripts. Proc. Natl. Acad. Sci. USA 110 (2013), E4088–E4097.